​

Annovis Bio (ANVS) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

ANVS Stock Forecast

Annovis Bio (ANVS) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $25.67, with a high of $30.00 and a low of $21.00. This represents a 2004.10% increase from the last price of $1.22.

- $6 $12 $18 $24 $30 High: $30 Avg: $25.67 Low: $21 Last Closed Price: $1.22

ANVS Stock Rating

Annovis Bio stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (77.78%), 2 Hold (22.22%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 2 7 Strong Sell Sell Hold Buy Strong Buy

ANVS Price Target Upside V Benchmarks

TypeNameUpside
StockAnnovis Bio2004.10%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.22$1.22$1.22
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 2612---3
Aug, 2612---3
Jul, 2611---2
Jun, 2611---2
May, 2611---2
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 16, 2024Raghuram SelvarajuH.C. Wainwright$30.00$8.82240.14%2359.02%
Aug 13, 2024Jason KolbertEF Hutton$21.00$7.87166.84%1621.31%
Apr 30, 2024Sumant KulkarniCanaccord Genuity$26.00$7.28257.14%2031.15%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 27, 2026Roth CapitalBuyBuyhold
Jul 07, 2026Roth CapitalBuyinitialise
Oct 01, 2024H.C. WainwrightBuyBuyhold
Sep 03, 2024Canaccord GenuityBuyBuyhold
Aug 13, 2024EF HuttonBuyinitialise
Jul 11, 2024H.C. WainwrightBuyBuyhold
Jul 02, 2024Rodman & RenshawBuyBuyhold
Jun 04, 2024Rodman & RenshawBuyinitialise

Financial Forecast

EPS Forecast

$-3K $-2K $-2K $-1K $-500 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-6.23$-2.02K$-1.40---
Avg Forecast$-5.65$-1.93$-1.86$-1.77$-2.65$-1.51
High Forecast$-5.51$-1.73$-1.15$-0.58$-0.56$-1.51
Low Forecast$-5.96$-2.13$-2.55$-2.76$-5.58$-1.51
Surprise %10.27%104485.49%-24.73%---

Revenue Forecast

$0 $50M $100M $150M $200M $250M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$10.95M$206.36M$70.60M
High Forecast---$10.95M$206.36M$70.60M
Low Forecast---$10.95M$206.36M$70.60M
Surprise %------

Net Income Forecast

$-30B $-24B $-18B $-12B $-6B $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-56.20M$-24.59M$-28.85B---
Avg Forecast$-51.73M$-17.40M$-16.70M$-15.05M$-27.71M$-13.59M
High Forecast$-49.72M$-15.61M$-10.40M$-5.21M$-5.04M$-13.59M
Low Forecast$-53.74M$-19.20M$-22.99M$-24.89M$-50.39M$-13.59M
Surprise %8.65%41.28%172706.44%---

ANVS Forecast FAQ

Is Annovis Bio stock a buy?

Annovis Bio stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Annovis Bio is a favorable investment for most analysts.

What is Annovis Bio's price target?

Annovis Bio's price target, set by 9 Wall Street analysts, averages $25.67 over the next 12 months. The price target range spans from $21 at the low end to $30 at the high end, suggesting a potential 2004.10% change from the previous closing price of $1.22.

How does Annovis Bio stock forecast compare to its benchmarks?

Annovis Bio's stock forecast shows a 2004.10% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Annovis Bio over the past three months?

  • September 2026: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Annovis Bio’s EPS forecast?

Annovis Bio's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.77, marking a 26.43% increase from the reported $-1.4 in 2025. Estimates for the following years are $-2.65 in 2027, and $-1.51 in 2028.

What is Annovis Bio’s revenue forecast?

Annovis Bio's average annual revenue forecast for its fiscal year ending in December 2026 is $10.95M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $206.36M, and $70.6M for 2028.

What is Annovis Bio’s net income forecast?

Annovis Bio's net income forecast for the fiscal year ending in December 2026 stands at $-15.05M, representing a -99.95% decrease from the reported $-28.854B in 2025. Projections indicate $-27.713M in 2027, and $-13.595M in 2028.